Overview:
HIV 1 & 2 Western Blot ProfileIntroduction: The HIV 1 & 2 Western Blot Profile is a diagnostic tool designed to confirm HIV infection using serum samples. Associated with conditions like HIV-1 and HIV-2 infections, these disorders present with fever, weight loss, and severe complications if untreated, particularly in individuals with suspected HIV. Per the 2023 Serology guidelines, the test employs serology with immunoassay technology, delivering detailed parameter analysis over 1-2 days with high sensitivity and specificity, making it a valuable tool for HIV screening in clinical settings. This diagnostic falls under HIV screening and targets individuals with positive initial HIV tests, addressing the challenge of accurate confirmation to guide treatment. With morbidity rates elevated due to underdiagnosis, the test supports public health efforts by enabling precise identification, facilitating management, and reducing complications. Its serum-based approach ensures reliable detection.
Other Names: HIV WB Pfl.
FDA Status: FDA approved, CLIA certified for serology, compliant with 2025 standards.
Historical Milestone: Introduced in the 1980s by virology labs, this test advanced HIV confirmation.
Purpose: The test screens for 13 parameters including HIV-1 gp120 to guide HIV assessment, assess viral proteins, and inform treatment and prevention strategies.
Test Parameters: 1. HIV-1 gp120, 2. HIV-1 gp41, 3. HIV-1 p66, 4. HIV-1 p51, 5. HIV-1 p31, 6. HIV-1 p24, 7. HIV-1 p17, 8. HIV-2 gp36, 9. HIV-2 gp105, 10. HIV-1/2 Envelope, 11. HIV-1/2 Core, 12. HIV-1/2 Polymerase, 13. HIV-1/2 Confirmatory Result.
Pretest Condition: No fasting required; patients should report fever, weight loss, or recent HIV exposure symptoms.
Specimen: 3 mL serum in 1 SST, transported within specified times to maintain sample viability.
Sample Stability at Room Temperature: 8 hours with proper handling to preserve analyte integrity, ensuring reliable test performance.
Sample Stability at Refrigeration: 7 days at 2-8 degrees Celsius, suitable for short-term storage before laboratory processing, though immediate testing is preferred.
Sample Stability at Frozen: 6 months at -20 degrees Celsius, allowing long-term storage for retesting, though freezing may affect some analytes.
Medical History: Patients should provide details on fever, weight loss, prior HIV reactions, or family history of infectious diseases, as well as any recent trauma or treatments.
Consent: Written informed consent is required, detailing the test's purpose, potential risks of untreated HIV including AIDS, benefits of early detection, and minimal discomfort from sample collection.
Procedural Considerations: The test involves sample processing using immunoassay and interpret results within 1-2 days using provided controls.
Factors Affecting Result Accuracy: Delays beyond stability periods, improper storage conditions, cross-contamination with other samples, or recent antiretroviral use can affect results. Correlation with clinical evaluation or additional testing is recommended to confirm findings.
Clinical Significance: Abnormal results indicate possible HIV infection, necessitating further investigation like specialist consultation or additional testing. Normal results may require follow-up if symptoms persist.
Specialist Consultation: General practitioners or specialists in infectious disease should be consulted for case management, treatment planning, and coordination with health programs.
Additional Supporting Tests: PCR or CD4 count for confirmation.
Test Limitations: The test may produce false negatives in early infection stages or false positives in cross-reactivity, requiring a comprehensive diagnostic approach that includes clinical correlation.
References: Serology Guidelines 2023, Journal of Infectious Diseases 2024, Biochemistry 2025.
